Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial.

Name: Αlpha¹ Rigor Record — Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial.
Item: Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial.
Rating: 59
Author: Αlpha¹

Donovan J, Duc Bang N, Dong HKT, Ho DTN, Nguyen TAT, Nguyen TTH, Lam HBN, Phung VKN, Nguyen TT, Nguyen HHH, Pham KNO, Do DAT, Nguyen TMT, Dang TMH, Nguyen HL, Nguyen VVC, Hoang TH, Tran DD, Phung KL, Ramakrishnan L, Le THN, Nguyen TTT, Wolbers M, Kestelyn E, Geskus RB, Nguyen HP, Thwaites GE

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 2 high issues for “Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
StatisticsPrinted percentage does not match its own count (capped) ×3−0.25★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced4 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Treatment effect not shown to be clinically meaningfulAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously designed and transparently reported phase 3 randomized controlled trial. The scientific premise is well-supported, the methodology is thorough, and data/code availability is exemplary. Minor reporting inconsistencies and a few copyedit issues do not undermine the overall integrity.

Both reviewers classified the study as interventional, and this was adopted. The evaluation covered all eight dimensions; several sub-criteria were marked not applicable (e.g., animal housing, cell line authentication) due to the human clinical trial nature. The statistics verification covered only a subset of tests (7 recomputed, 4 consistent, 3 not machine-verifiable); no decision errors were found. The citation check flagged one reference as not found in registry (the Dryad DOI), which is a data repository link rather than a citation.

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: effect size not shown to be clinically meaningful.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks. 3 printed percentages that do not match their own count.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites the 2004 dexamethasone trial, substudies showing heterogeneity, and genetic studies linking LTA4H genotypes to inflammation and dexamethasone response. It acknowledges limitations of prior work (e.g., post-hoc analyses, uncertain benefit in HIV-positive, heterogeneity) and explains how the trial addresses these gaps by stratifying by genotype. The rationale for the hybrid noninferiority/superiority design is clearly linked to the premise.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a strong scientific premise by citing prior research on LTA4H genotype and corticosteroid response, and clearly links this to the trial's objectives.

Evidence

paraphrase[Main, paragraphs 2-4]

“Genetic analysis of a subset of the Vietnam dexamethasone trial participants and subsequent tuberculous meningitis cohorts found that LTA4H genotypes were associated with distinct intracerebral inflammatory phenotypes and dexamethasone responsiveness in HIV-negative individuals but not in those living with HIV.”

direct quote[Main, paragraph 5]

“We therefore conducted a LTA4H -genotype stratified randomized placebo-controlled trial of dexamethasone in HIV-negative Vietnamese adults with tuberculous meningitis.”